CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- 4 Open-market sale Chief Financial Officer sold 6,255 shares at an average $4.49 ($28,086)
- 4 Open-market sale President and CEO sold 14,806 shares at $5.04 ($74,548)
- 4 Open-market sale EVP, Head of R&D sold 4,124 shares at $5.03 ($20,760)
- 4 Open-market sale SVP, GC & Secretary sold 3,430 shares at an average $5.03 ($17,269)
- 4 Open-market sale Chief Financial Officer sold 5,940 shares at $5.04 ($29,908)
- 4 Open-market sale President and CEO sold 14,220 shares at $7.20 ($102,384)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Grant or award Director acquired 20,500 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 5,853 shares at $5.63 ($32,952)
- 4 Open-market sale SVP, GC & Secretary sold 3,223 shares at an average $5.32 ($17,134)
- 4 Open-market sale Chief Financial Officer sold 5,582 shares at an average $5.32 ($29,675)
- 4 Open-market sale EVP, Head of R&D sold 3,873 shares at $5.32 ($20,597)
- 4 Open-market sale President and CEO sold 13,913 shares at $5.32 ($73,962)
Page 7 of 33 · 644 filings